Every MT-2 (Melanotan II) Question Answered, in 21 Studies

21 referenced articles

• What Before-and-After Photographs Can and Cannot Show3 sources
• Melanotan 2 Nasal Spray and Why the Dose Is Unknowable3 sources
• Why This Site Publishes No Melanotan 2 Dose4 sources
• Melanotan 2 Onset: What Can and Cannot Be Said3 sources
• Does Melanotan 2 Work Without UV?4 sources
• The Receptor That Decides Which Pigment Is Made3 sources
• Melanotan 2 Storage, Mixing and Stability3 sources
• Is Melanotan 2 Safe? What Has Actually Been Published3 sources
• Melanotan 1 vs Melanotan 2 Are Not the Same Compound4 sources
• What Is Melanotan 2? Structure, Origin and Status4 sources
• The Receptor a Non-Selective Agonist Also Reaches3 sources
• The Pharmacology Works. This Compound Was Not Developed.4 sources
• A Third Approved Melanocortin Medicine3 sources
• Alpha-MSH Engages Four of Five, Not All of Them3 sources
• A 1995 Paper, and a Structure That Checks Out Exactly3 sources
• MT-2 Regulatory Status4 sources
• MT-2 Chemical Identity and the Database Trap3 sources
• What an Approved Melanocortin Agonist Looks Like3 sources
• Two Compounds, One Parent, Opposite Intentions4 sources
• Five Melanocortin Receptors, Not One3 sources
• MT-2 Structure: Four Stability Features in Seven Residues3 sources

Open research questions

• Why does searching for melanotan return an approved medicine?
• What is the difference between Melanotan I and Melanotan II?
• How do four separate modifications make one small peptide protease-resistant?
• What are the five melanocortin receptors and where are they?
• How do MT-2 and KPV relate through their shared parent hormone?
• What does the published dermatology literature actually report?

Deep dive: the identifier collision that points the wrong way

This site has now found several plausible-looking identifiers that resolve to the wrong molecule. A PubChem record for tirzepatide cited as retatrutide. Thymosin beta-4's CAS quoted as TB-500's. An unrelated organic acid returned for KPV. This one is the most consequential of the set, and the reason is direction. Searching PubChem for melanotan returns CID 16197727 - afamelanotide, at 1,646.8 Da for C78H111N21O19. That is Melanotan I, a linear thirteen-residue peptide, and it is an APPROVED MEDICINE, marketed as Scenesse for erythropoietic protoporphyria. Melanotan II is CID 92432: cyclic, seven residues, 1024.2 Da, 622 Da lighter, and assessed by no regulator anywhere. So the wrong record does not merely mislead about mass. It resolves from an unlicensed compound toward a licensed one, and the sequential naming - I and II - makes them look like versions of a single product rather than the structurally distinct compounds they are. Anyone verifying a certificate by searching the bare name lands on an approved drug's record and may never notice which compound it names.

Deep dive: four stability features in seven residues

PubChem's IUPAC name for CID 92432 is unusually complete and reads as a full specification: N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysinamide, cyclic (2-7)-peptide. Unpack it and there are four independent protease-resistance features in a molecule of seven residues. A lactam bridge joins the aspartate side chain at position 2 to the lysine side chain at position 7, closing the ring - which both locks conformation for receptor engagement and eliminates the free termini exopeptidases require. Position 4 is D-phenylalanine, the mirror image of the natural form, and proteases are stereospecific enough that they largely cannot process it. The N-terminus is acetylated and the C-terminus amidated, capping both ends. And position 1 is norleucine, which is not among the twenty proteinogenic amino acids at all - so even setting aside the cyclisation and the D residue, this peptide could never have been a gene product. It is a fully synthetic construction rather than a modified natural sequence, and it is among the most chemically robust compounds in this catalogue as a direct result.

Deep dive: why the safety literature is included rather than omitted

There is a published dermatological literature here, and the editorial choice was to state it. Reid and colleagues documented atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013. Eijmael and colleagues published a risk review in the Nederlands Tijdschrift voor Geneeskunde in 2022 - a national medical journal considering the topic worth addressing directly. Case reports have a real limitation: they establish an observation without a denominator, so they cannot establish causation or incidence, which is the same constraint that applies to pharmacovigilance disproportionality signals. But that limitation cuts both ways. A case report is not proof of harm and it is not dismissible either. What makes the absence of better data significant here is that no regulator has assessed this compound - so there is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist for an injectable product simply does not, and what is available instead is what individual clinicians chose to publish after seeing something. Presenting the compound without that context would give an incomplete picture of what is actually known.

Handling checklist

• Verify against CID 92432, 1024.2 Da, C50H69N15O9, CAS 121062-08-6
• Never verify by searching 'melanotan' alone - that returns afamelanotide at 1,646.8 Da
• Require stereochemistry on the certificate - D-Phe4 is not detectable by mass
• Protect from light; tryptophan at position 6 is photochemically reactive
• Store lyophilised, cold, dry and dark
• Expect no disulfide or oxidation satellites - no cysteine, no methionine
• Quantification at 280 nm is available thanks to the tryptophan

Common mistakes

Searching PubChem for 'melanotan' to verify identity

That returns CID 16197727, afamelanotide, at 1,646.8 Da - an approved medicine and a different molecule. Use CID 92432 or search Melanotan II with the numeral.

Treating Melanotan I and II as versions of one compound

They differ by 622 Da, by six residues, and by whether the peptide is cyclic or linear. Only Melanotan I has been assessed by regulators.

Reading afamelanotide's approval as covering MT-2

Different molecule, different structure, different evidence, different assessment. Nothing transfers.

Accepting a sequence written without stereochemistry

L- and D-phenylalanine have identical mass. A peptide with the L form at position 4 is a different compound that mass spectrometry cannot distinguish.

Assuming a non-selective agonist affects only its intended receptor

Five melanocortin receptors share binding surfaces across different tissues. Engagement elsewhere is the same pharmacology in another place, not a side reaction.